Biogen Inc. (BIIB)
| Market Cap | 28.84B +50.8% |
| Revenue (ttm) | 9.94B +1.2% |
| Net Income | 1.37B -7.3% |
| EPS | 9.30 -8.1% |
| Shares Out | 147.64M |
| PE Ratio | 21.01 |
| Forward PE | 14.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 880,369 |
| Open | 196.45 |
| Previous Close | 196.45 |
| Day's Range | 195.14 - 200.66 |
| 52-Week Range | 121.05 - 205.97 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | 219.44 (+12.34%) |
| Earnings Date | Apr 29, 2026 |
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe... [Read more]
Financial Performance
In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.
Financial StatementsAnalyst Summary
According to 36 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price target is $219.44, which is an increase of 12.34% from the latest price.
News
Biogen granted Breakthrough Therapy Designation for salanersen by FDA
Biogen (BIIB) announced that the FDA has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular atrophy, or SMA.
Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Designation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene therapy who had suboptimal clinical status experienced slow...
UCB, Biogen announce dapirolizumab pegol data at EULAR
UCB and Biogen (BIIB) announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology, or EULAR, 2026 Congress, demonstrating the clinical profile...
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, ...
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that fourteen abstracts highlighting data from its nephrology portfolio, including EMPAVELI® (pegcetacoplan) an...
Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.
The drug industry has been working on how to shuttle drugs through the blood-brain barrier, and the results will become apparent this year.
Biogen, UCB publishes full results from PHOENYCS GO clinical trial in The Lancet
UCB and Biogen (BIIB) announced that The Lancet has published the full results from the Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol, an investigational Fc-free CD40L inhibitor, i...
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
BRUSSELS, Belgium and CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced that The Lancet, a world-leading medical journal, ...
Biogen price target raised to $227 from $222 at RBC Capital
RBC Capital raised the firm’s price target on Biogen (BIIB) to $227 from $222 and keeps an Outperform rating on the shares. The firm is citing findings from its multi-symposium…
Italy's antitrust regulator opens probe into US Biogen over alleged dominant position
Italy's antitrust authority said on Wednesday it had opened an investigation into drug maker Biogen Italia and its parent Biogen over alleged abuse of dominant position.
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study
Biogen and Denali Therapeutics said on Thursday they will discontinue development of their Parkinson's drug after it failed to meet the main goal in a mid-to-late stage study.
Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints
Biogen (BIIB) and Denali Therapeutics (DNLI) announced topline results from the Phase 2b LUMA study evaluating BIIB122, an investigational small molecule inhibitor of LRRK2, in individuals with early-...
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced topline results from the Phase...
Biogen resumed with an Outperform at Evercore ISI
Evercore ISI resumed coverage of Biogen (BIIB) with an Outperform rating. Biogen’s recent update “brings a mix of insights regarding the tau program for Alzheimer’s treatment” and while the primary…
Biogen price target raised to $225 from $214 at Piper Sandler
Piper Sandler raised the firm’s price target on Biogen (BIIB) to $225 from $214 and keeps an Overweight rating on the shares. The firm notes Biogen announced that its Phase…
Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
H.C. Wainwright views Biogen’s (BIIB) CELIA topline results as “historic,” noting that diranersen is the first tau-targeting therapy to demonstrate both replicable tau pathology reduction and directio...
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
Biogen plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen plans to move it into Phase 3 t...
Biogen completes acquisition of Apellis Pharmaceuticals
Biogen (BIIB) announced the successful completion of the acquisition of Apellis Pharmaceuticals (APLS). Apellis is now a wholly owned subsidiary of Biogen. In connection with the merger, the shares th...
Biogen’s diranersen shows benefits in early Alzheimer’s Disease
Biogen (BIIB) announced “compelling” topline results from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide therapy targeting tau, in individuals with early A...
Ionis announces Biogen’s CELIA study did not meet primary endpoint
Ionis Pharmaceuticals (IONS) announced that its partner, Biogen (BIIB), shared compelling topline results from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleoti...
Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.
Biogen's diranersen showed ‘robust reductions' in key biomarkers during a Phase 2 trial, the biotech said.
Biogen Completes Acquisition of Apellis Pharmaceuticals
CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a l...
Biogen up 8% at $220 after Phase 2 diranersen data in Alzheimer’s Disease
07:23 EDT Biogen (BIIB) up 8% at $220 after Phase 2 diranersen data in Alzheimer’s Disease
Biogen's Alzheimer's drug fails to meet mid-stage trial goal
Biogen said on Thursday its Alzheimer's drug did not meet the main goal of a mid-stage trial.
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease
Robust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study1 Pre-specified analyses of cognitive endpoints de...